34 results on '"Gennaro Colella"'
Search Results
2. Supplementary Figure 4 from The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
- Author
-
Giovanna Damia, Gabriella Camboni, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Petra Richter, Alexander Berndt, Simonetta A. Licandro, Daniele Forestieri, Massimo Zucchetti, Gennaro Colella, Giulia Taraboletti, and Ezia Bello
- Abstract
PDF file - 63KB, Circulating factors in plasma of mice bearing MDA-MB-231 tumors untreated or treated with E-3810 (E), brivanib (B), sunitinib (S), paclitaxel (PTX) and their combinations as described in Material amd Methods.
- Published
- 2023
3. Supplementary Figure 2 from The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
- Author
-
Giovanna Damia, Gabriella Camboni, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Petra Richter, Alexander Berndt, Simonetta A. Licandro, Daniele Forestieri, Massimo Zucchetti, Gennaro Colella, Giulia Taraboletti, and Ezia Bello
- Abstract
PDf file - 30KB, Survival curves of MDA-MB-231 bearing mice treated with E-3810, PTX and their combination.
- Published
- 2023
4. Supplementary Figure 3 from The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
- Author
-
Giovanna Damia, Gabriella Camboni, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Petra Richter, Alexander Berndt, Simonetta A. Licandro, Daniele Forestieri, Massimo Zucchetti, Gennaro Colella, Giulia Taraboletti, and Ezia Bello
- Abstract
PDF file - 41KB, Dose response curve of PTX in MDA-MB-231 cells alone or in combination with E-3810, sunitinb and brivanib.
- Published
- 2023
5. Supplementary Methods and Figure Legends from The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
- Author
-
Giovanna Damia, Gabriella Camboni, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Petra Richter, Alexander Berndt, Simonetta A. Licandro, Daniele Forestieri, Massimo Zucchetti, Gennaro Colella, Giulia Taraboletti, and Ezia Bello
- Abstract
PDF file - 101KB
- Published
- 2023
6. Supplementary Table 1 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Author
-
Gabriella Camboni, Giovanna Damia, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Sonia Colombo Serra, Giovanni Valbusa, Alexander Berndt, Paolo Oliva, Valentina Scarlato, Gennaro Colella, and Ezia Bello
- Abstract
Supplementary Table 1 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Published
- 2023
7. Supplementary Figures 1-4 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Author
-
Gabriella Camboni, Giovanna Damia, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Sonia Colombo Serra, Giovanni Valbusa, Alexander Berndt, Paolo Oliva, Valentina Scarlato, Gennaro Colella, and Ezia Bello
- Abstract
Supplementary Figures 1-4 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Published
- 2023
8. Supplementary Table 2 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Author
-
Gabriella Camboni, Giovanna Damia, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Sonia Colombo Serra, Giovanni Valbusa, Alexander Berndt, Paolo Oliva, Valentina Scarlato, Gennaro Colella, and Ezia Bello
- Abstract
Supplementary Table 2 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Published
- 2023
9. Supplementary Methods, Figure Legends 1-4 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Author
-
Gabriella Camboni, Giovanna Damia, Raffaella Giavazzi, Ennio Cavalletti, Maurizio D'Incalci, Sonia Colombo Serra, Giovanni Valbusa, Alexander Berndt, Paolo Oliva, Valentina Scarlato, Gennaro Colella, and Ezia Bello
- Abstract
Supplementary Methods, Figure Legends 1-4 from E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Published
- 2023
10. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma
- Author
-
Rihan El Bezawy, Stefano Percio, Chiara Maura Ciniselli, Michelandrea De Cesare, Gennaro Colella, Matteo Dugo, Silvia Veneroni, Valentina Doldi, Silvia Martini, Dario Baratti, Shigeki Kusamura, Paolo Verderio, Marcello Deraco, Paolo Gandellini, Nadia Zaffaroni, and Valentina Zuco
- Subjects
Male ,Cancer Research ,Lung Neoplasms ,Mesothelioma, Malignant ,Prognosis ,Gene Expression Regulation, Neoplastic ,Mice ,MicroRNAs ,Cell Movement ,Cell Line, Tumor ,Molecular Medicine ,Animals ,Humans ,HSP90 Heat-Shock Proteins ,RNA, Messenger ,Molecular Biology ,Biomarkers ,Peritoneal Neoplasms ,Cell Proliferation - Abstract
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and rapidly lethal tumor, poorly responsive to conventional treatments. In this regards, the identification of molecular alterations underlying DMPM onset and progression might be exploited to develop novel therapeutic strategies. Here, we focused on miR-550a-3p, which we found downregulated in 45 DMPM clinical samples compared to normal tissues and whose expression levels were associated with patient outcome. Through a gain-of-function approach using miRNA mimics in 3 DMPM cell lines, we demonstrated the tumor-suppressive role of miR-550a-3p. Specifically, miRNA ectopic expression impaired cell proliferation and invasiveness, enhanced the apoptotic response, and reduced the growth of DMPM xenografts in mice. Antiproliferative and proapoptotic effects were also observed in prostate and ovarian cancer cell lines following miR-550a-3p ectopic expression. miR-550a-3p effects were mediated, at least in part, by the direct inhibition of HSP90AA1 and the consequent downregulation of its target proteins, the levels of which were rescued upon disruption of miRNA-HSP90AA1 mRNA pairing, partially abrogating miR-550a-3p-induced cellular effects. Our results show that miR-550a-3p reconstitution affects several tumor traits, thus suggesting this approach as a potential novel therapeutic strategy for DMPM.
- Published
- 2021
11. Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours
- Author
-
Serge Leyvraz, D. Liénard, F. Shen, M. Bonfanti, Catia Marzolini, L. Perey, Marc Gander, Maurizio D'Incalci, Ferdy J. Lejeune, Gennaro Colella, Jérôme Biollaz, D. Yarosh, Laurent-Arthur Decosterd, and M. Belanich
- Subjects
Adult ,Male ,Dacarbazine ,medicine.medical_treatment ,Pharmacology ,Drug Administration Schedule ,Nitrosourea Compounds ,Adult Aged Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/pharmacokinetics/pharmacology Brain Neoplasms/blood/drug therapy/enzymology Dacarbazine/administration & dosage/adverse effects/analogs & derivatives Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance, Neoplasm Female Glioma/blood/drug therapy/enzymology Humans Lymphocytes/*enzymology Male Melanoma/blood/drug therapy/enzymology Middle Aged Nitrosourea Compounds/administration & dosage/adverse effects O(6)-Methylguanine-DNA Methyltransferase/*blood Organophosphorus Compounds/administration & dosage/adverse effects ,O(6)-Methylguanine-DNA Methyltransferase ,Organophosphorus Compounds ,Pharmacokinetics ,Oral administration ,Antineoplastic Combined Chemotherapy Protocols ,Temozolomide ,medicine ,Humans ,Lymphocytes ,Melanoma ,Aged ,Chemotherapy ,Dose-Response Relationship, Drug ,Brain Neoplasms ,business.industry ,Glioma ,Hematology ,Middle Aged ,Drug interaction ,Oncology ,Drug Resistance, Neoplasm ,Toxicity ,Fotemustine ,Female ,business ,medicine.drug - Abstract
Summary Background: The DNA repair protein O 6 -alkylguanine-DNA alkyl transferase (AT) mediates resistance to chloroethylnitrosoureas. Agents depleting AT such as DTIC and its new analogue temozolomide (TMZ) can reverse resistance to chloroethylnitrosoureas. We report the results of a dose finding study of TMZ in association with fotemustine. Patients and methods: Twenty-four patients with metastatic melanoma or recurrent glioma were treated with escalating dose of oral or intravenous TMZ ranging from 300 to 700 mg/m 2 , divided over two days. Fotemustine 100 mg/m 2 was given intravenously on day 2, 4 hours after TMZ. AT depletion was measured in peripheral blood mononuclear cells (PBMCs) and in selected cases in melanoma metastases and was compared to TMZ pharmacokinetics. Results: The maximum tolerated dose (MTD) of TMZ was 400 mg/m 2 (200 mg/m 2 /d) when associated with fotemustine the 2nd day with myelosuppression as dose limiting toxicity. The decrease of AT level in PBMCs was progressive and reached 34% of pretreatment values on day 2. There was however wide interindividual variability. AT reduction was neither dose nor route dependent and did not appear to be related to TMZ systemic exposure (AUC). In the same patients, AT depletion in tumour did not correlate with the decrease of AT observed in PBMCs. Conclusions: PBMCs may not be used as a surrogate of tumour for AT depletion. Further study should concentrate on the pharmacokinetic pharmacodynamic relationship in tumour to provide the basis for individually tailored therapy.
- Published
- 2017
12. E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- Author
-
Ennio Cavalletti, Ezia Bello, Giovanna Damia, Gabriella Camboni, Maurizio D'Incalci, Raffaella Giavazzi, Valentina Scarlato, Paolo Oliva, Alexander Berndt, Giovanni Valbusa, Sonia Colombo Serra, and Gennaro Colella
- Subjects
Cancer Research ,Angiogenesis ,Drug Evaluation, Preclinical ,Mice, Nude ,Antineoplastic Agents ,Pharmacology ,Fibroblast growth factor ,Models, Biological ,2-Pyridinylmethylsulfinylbenzimidazoles ,Mice ,chemistry.chemical_compound ,Neoplasms ,medicine ,Animals ,Humans ,Receptor ,Protein Kinase Inhibitors ,Cells, Cultured ,Chemistry ,Kinase ,Sunitinib ,Hep G2 Cells ,Receptors, Fibroblast Growth Factor ,Xenograft Model Antitumor Assays ,Vascular endothelial growth factor ,Receptors, Vascular Endothelial Growth Factor ,Oncology ,Fibroblast growth factor receptor ,Rabeprazole ,NIH 3T3 Cells ,Phosphorylation ,Female ,HT29 Cells ,medicine.drug - Abstract
Tumor angiogenesis is a degenerate process regulated by a complex network of proangiogenic factors. Existing antiangiogenic drugs used in clinic are characterized by selectivity for specific factors. Antiangiogenic properties might be improved in drugs that target multiple factors and thereby address the inherent mechanistic degeneracy in angiogenesis. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) family members and their cognate receptors are key players in promoting tumor angiogenesis. Here we report the pharmacologic profile of E-3810, a novel dual inhibitor of the VEGF and FGF receptors. E-3810 potently and selectively inhibited VEGF receptor (VEGFR)-1, -2, and -3 and FGF receptor (FGFR)-1 and -2 kinases in the nanomolar range. Ligand-dependent phosphorylation of VEGFR-2 and FGFR-1 was suppressed along with human vascular endothelial cell growth at nanomolar concentrations. In contrast, E-3810 lacked cytotoxic effects on cancer cell lines under millimolar concentrations. In a variety of tumor xenograft models, including early- or late-stage subcutaneous and orthotopic models, E-3810 exhibited striking antitumor properties at well-tolerated oral doses administered daily. We found that E-3810 remained active in tumors rendered nonresponsive to the general kinase inhibitor sunitinib resulting from a previous cycle of sunitinib treatment. In Matrigel plug assays performed in nude mice, E-3810 inhibited basic FGF–induced angiogenesis and reduced blood vessel density as assessed by histologic analysis. Dynamic contrast-enhanced magnetic resonance imaging analysis confirmed that E-3810 reduced the distribution of angiogenesis-sensitive contrast agents after only 5 days of treatment. Taken together, our findings identify E-3810 as a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity, providing a strong rationale for its clinical evaluation. Cancer Res; 71(4); 1396–405. ©2011 AACR.
- Published
- 2011
13. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810
- Author
-
Maurizio Pasi, Saverio Minucci, Mario Varasi, Gennaro Colella, Daniele Fancelli, Mara Colzani, Roberta Noberini, Mauro Romanenghi, and Tiziana Bonaldi
- Subjects
Proteomics ,Vascular Endothelial Growth Factor A ,Context (language use) ,Biology ,Naphthalenes ,Biochemistry ,Mass Spectrometry ,Analytical Chemistry ,Receptor-Interacting Protein Serine-Threonine Kinase 2 ,Stable isotope labeling by amino acids in cell culture ,medicine ,Humans ,Molecular Targeted Therapy ,Receptor ,Molecular Biology ,Protein Kinase Inhibitors ,Kinase ,Research ,In vitro toxicology ,Neoplasm Proteins ,Mechanism of action ,Fibroblast growth factor receptor ,Isotope Labeling ,Quinolines ,medicine.symptom - Abstract
Novel drugs are designed against specific molecular targets, but almost unavoidably they bind non-targets, which can cause additional biological effects that may result in increased activity or, more frequently, undesired toxicity. Chemical proteomics is an ideal approach for the systematic identification of drug targets and off-targets, allowing unbiased screening of candidate interactors in their natural context (tissue or cell extracts). E-3810 is a novel multi-kinase inhibitor currently in clinical trials for its anti-angiogenic and anti-tumor activity. In biochemical assays, E-3810 targets primarily vascular endothelial growth factor and fibroblast growth factor receptors. Interestingly, E-3810 appears to inhibit the growth of tumor cells with low to undetectable levels of these proteins in vitro, suggesting that additional relevant targets exist. We applied chemical proteomics to screen for E-3810 targets by immobilizing the drug on a resin and exploiting stable isotope labeling by amino acids in cell culture to design experiments that allowed the detection of novel interactors and the quantification of their dissociation constant (Kd imm) for the immobilized drug. In addition to the known target FGFR2 and PDGFRα, which has been described as a secondary E-3810 target based on in vitro assays, we identified six novel candidate kinase targets (DDR2, YES, LYN, CARDIAK, EPHA2, and CSBP). These kinases were validated in a biochemical assay and—in the case of the cell-surface receptor DDR2, for which activating mutations have been recently discovered in lung cancer—cellular assays. Taken together, the success of our strategy—which integrates large-scale target identification and quality-controlled target affinity measurements using quantitative mass spectrometry—in identifying novel E-3810 targets further supports the use of chemical proteomics to dissect the mechanism of action of novel drugs.
- Published
- 2014
14. Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis
- Author
-
Carla Manzotti, L. Orlandi, Gennaro Colella, A. Bearzatto, Gabriella Abolafio, Maria Grazia Daidone, and Nadia Zaffaroni
- Subjects
Cancer Research ,Programmed cell death ,Pathology ,medicine.medical_specialty ,Organoplatinum Compounds ,DNA damage ,Immunoblotting ,Antineoplastic Agents ,Apoptosis ,Cyclin B ,Biology ,CDC2 Protein Kinase ,Tumor Cells, Cultured ,medicine ,Humans ,Cyclin B1 ,Kinase activity ,Electrophoresis, Agar Gel ,Ovarian Neoplasms ,Cisplatin ,Cell growth ,Cell Cycle ,Cell cycle ,Molecular biology ,Oncology ,Drug Resistance, Neoplasm ,Cell culture ,Female ,medicine.drug - Abstract
We evaluated the effects of the trinuclear platinum complex, BBR 3464, in a human ovarian carcinoma cell line (OAW42) and in its cisplatin (CDDP)-resistant counterpart (OAW42MER). A 14-fold increased sensitivity to a 1-h BBR 3464 exposure was found in OAW42MER cells compared with their parental cell line. Flow cytometric experiments showed that BBR 3464 was able to induce a persistent block of OAW42 and OAW42MER cells in the G 2 M phase, whereas CDDP caused an initial accumulation of cells in the S phase followed by an increase in the G 2 M cell fraction in both cell lines. Exposure to equitoxic (IC 50 ) drug concentrations induced programmed cell death in both cell lines. However, the percentage of cells with an apoptotic nuclear morphology was slightly higher after CDDP than BBR 3464 treatment in OAW42 cells, whereas the opposite pattern was observed in OAW42MER cells. Degradation of the nuclear lamin B was detected in OAW42 cells after exposure to each drug. Conversely, in OAW42MER cells lamin B cleavage was only appreciable after BBR 3464 exposure. In OAW42 cells, CDDP and BBR 3464 did not appreciably affect the mitochondrial membrane potential (Δψ mt ), whereas in the OAW42MER cell line a marked Δψ mt reduction was observed after exposure to BBR 3464, but not to CDDP. The results of the study would suggest that the sensitivity to BBR 3464 observed in the CDDP-resistant OAW42MER cell line might be attributable to the ability of the trinuclear platinum complex to modify DNA in a way which is different from that of CDDP and, as a consequence, to induce different cellular responses to DNA damage such as the triggering of specific apoptotic pathways.
- Published
- 2001
15. Inhibition of Telomerase Activity by a Hammerhead Ribozyme Targeting the RNA Component of Telomerase in Human Melanoma Cells
- Author
-
Gennaro Colella, Marco Folini, Maria Grazia Daidone, Nadia Zaffaroni, Raffaella Villa, and Susanna Lualdi
- Subjects
telomere ,Telomerase ,Hammerhead ribozyme ,gene expression vector ,Ribozyme ,Cell Biology ,Dermatology ,Biology ,biology.organism_classification ,Molecular biology ,Biochemistry ,Telomere ,Telomerase RNA component ,Phenotype ,cationic liposome ,Tumor Cells, Cultured ,biology.protein ,Humans ,RNA ,RNA, Catalytic ,Telomerase reverse transcriptase ,Mammalian CPEB3 ribozyme ,Molecular Biology ,VS ribozyme - Abstract
Reactivation of telomerase, an RNA-dependent DNA polymerase that synthesizes new telomeric repeats at the end of chromosomes, is a very common feature in human cancers. Telomerase is thought to be essential in maintaining the proliferative capacity of tumor cells and, as a consequence, it could represent an attractive target for new anti-cancer therapies. In this study, we generated a hammerhead ribozyme composed of a catalytic domain with flanking sequences complementary to the RNA component of human telomerase and designed to cleave specifically a site located at the end of the telomerase template sequence. In vitro the ribozyme induced cleavage of a synthetic RNA substrate obtained by cloning a portion of the RNA component of human telomerase. The extent of cleavage was dependent on the ribozyme/substrate ratio as well as the Mg2+ concentration. Moreover, when added to cell extracts from two human melanoma cell lines (JR8 and M14), or three melanoma surgical specimens, the ribozyme inhibited telomerase activity in a concentration- and time-dependent manner. When the ribozyme was delivered to growing JR8 melanoma cells by (N-(1-(2,3 dioleoxyloxy)propil)-N,N,N trimethylammonium methylsulfate-mediated transfer, a marked inhibition of telomerase activity was observed. Next, the ribozyme sequence was cloned in an expression vector and JR8 cells were transfected with it. The cell clones obtained showed a reduced telomerase activity and telomerase RNA levels and expressed the ribozyme. Moreover, ribozyme transfectants had significantly longer doubling times than control cells and showed a dendritic appearance in monolayer culture. No telomere shortening, however, was observed in these clones. Overall, our results indicate that the hammerhead ribozyme is a potentially useful tool for the inactivation of telomerase in human tumors.
- Published
- 2000
- Full Text
- View/download PDF
16. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
- Author
-
Gennaro Colella, Maurizio D'Incalci, Robert S. Brown, Sergio Marchini, and Massimo Broggini
- Subjects
Cancer Research ,DNA Repair ,Base Pair Mismatch ,minor groove binders ,Biology ,Adenocarcinoma ,medicine.disease_cause ,chemistry.chemical_compound ,alkylating agents ,medicine ,Tumor Cells, Cultured ,Humans ,Antineoplastic Agents, Alkylating ,Genetics ,Cisplatin ,Ovarian Neoplasms ,Mutation ,Carzelesin ,Tallimustine ,Regular Article ,mismatch repair ,Oncology ,chemistry ,Cell culture ,Drug Resistance, Neoplasm ,Cancer research ,DNA mismatch repair ,Female ,Colorectal Neoplasms ,Groove (joinery) ,DNA ,medicine.drug - Abstract
Mismatch DNA repair deficiency is associated with resistance to certain major groove alkylating agents including methylating agents and cisplatin. We have now studied the relevance of mismatch repair alterations to the cytotoxicity induced by drugs which alkylate N3 adenines in the minor groove of DNA. We have used the mismatch repair defective human colocarcinoma cell line HCT-116 which has a mutation in the hMLH1 gene, and a subline where hMLH1 expression is restored by chromosome 3 transfer (HCT-116+ch3). We have tested three alkylating minor groove binders (tallimustine, carzelesin and CC1065) and one non-covalent minor groove binder (PNU 151807). The HCT-116+ch3 subline was more sensitive than the parental line to the treatment with the three alkylating minor groove binders, while the non-alkylating compound had a similar activity in both cell lines. Further support for mismatch repair being involved in sensitivity of the minor groove alkylators is that two cisplatin-resistant sublines of the human ovarian adenocarcinoma cell line A2780 (A2780/CP70 and A2780/MCP-1) are defective in hMLH1 expression and are more resistant to these agents than the parental mismatch repair proficient cells. Furthermore, the restoration of hMLH1 activity in the A2780/CP70 cell line, by introduction of chromosome 3, was associated with an increased sensitivity to the three alkylating minor groove binders. Again, the non-covalent minor groove binder was equally effective in mismatch repair deficient and proficient clones. The data indicate that mismatch repair deficiency mediated by loss of hMLH1 expression is associated not only with drug-resistance to major groove binders, but also to minor groove binders. However, loss of mismatch repair does not mediate resistance to the non-covalent minor groove binder PNU 151807. © 1999 Cancer Research Campaign
- Published
- 1999
17. Characterization of a protein recognizing minor groove binders-damaged DNA
- Author
-
Massimo Broggini, Maurizio D'Incalci, M. Bonfanti, Gennaro Colella, Colella, Giuseppe, Bonfanti, M, D'Incalci, M, and Broggini, M.
- Subjects
DNA damage ,Antineoplastic Agents ,Biology ,Topoisomerase-I Inhibitor ,DNA-binding protein ,Cell Line ,Jurkat Cells ,Mice ,chemistry.chemical_compound ,Cricetinae ,Tumor Cells, Cultured ,Genetics ,Animals ,Humans ,Electrophoretic mobility shift assay ,Melphalan ,Binding Sites ,Topoisomerase ,Distamycins ,DNA ,Molecular biology ,Intercalating Agents ,DNA-Binding Proteins ,Mice, Inbred C57BL ,Biochemistry ,chemistry ,Nitrogen Mustard Compounds ,Bisbenzimidazole ,biology.protein ,Electrophoresis, Polyacrylamide Gel ,Topoisomerase-II Inhibitor ,Research Article ,DNA Damage ,Nucleotide excision repair - Abstract
By using electromobility shift assay (EMSA), we have identified a protein able to recognize the DNA only if it was previously reacted with minor groove binders. This protein binds with very high affinity AT containing DNA treated with minor groove binders such as distamycin A, Hoechst 33258 and 33342, CC-1065 and ethidium bromide minor groove intercalator, but not with major groove binders such as quinacrine mustard, cisplatin or melphalan, or with topoisomerase I inhibitor camptothecin or topoisomerase II inhibitor doxorubicin. This protein was found to be present in different extracts of human, murine and hamster cells, with the human protein which appears to have a molecular weight slightly lower than that of the other species. This protein was found to be expressed both in cancer and normal tissues. By using molecular ultrafiltration techniques as well as southwestern analysis it was estimated that the apparent molecular weight is close to 100 kDa. We can exclude an identity between this protein and other proteins, with a similar molecular weight previously reported to be involved in DNA damage recognition/repair, such as topoisomerase I, mismatch repair activities such as the prokaryotic MutS protein and its human homologue hMSH2 or proteins of the nucleotide excision repair system such as ERCC1, -2, -3 and -4.
- Published
- 1996
18. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts
- Author
-
Maurizio D'Incalci, Giovanna Damia, Gennaro Colella, Ezia Bello, Daniele Forestieri, Simonetta Andrea Licandro, Giulia Taraboletti, Gabriella Camboni, Ennio Cavalletti, Petra Richter, Alexander Berndt, Raffaella Giavazzi, Massimo Zucchetti, Bello, E, Taraboletti, G, Colella, G, Zucchetti, M, Forestieri, D, Licandro, S, Berndt, A, Richter, P, D'Incalci, M, Cavalletti, E, Giavazzi, R, Camboni, G, and Damia, G
- Subjects
Cancer Research ,Indoles ,Paclitaxel ,medicine.drug_class ,Alanine, Animals, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Drug Synergism, Female, Humans, Indoles, Mice, nude, Paclitaxel, Protein Kinase Inhibitors, Pyrroles, Rabeprazole, Random Allocation, Sunitinib, Triazines, Triple Negative Breast Neoplasms, Xenograft Model Antitumor Assays ,Mice, Nude ,Triple Negative Breast Neoplasms ,Pharmacology ,Tyrosine-kinase inhibitor ,chemistry.chemical_compound ,Mice ,Random Allocation ,Pharmacokinetics ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Sunitinib ,Animals ,Humans ,Pyrroles ,Protein Kinase Inhibitors ,Triple-negative breast cancer ,Cisplatin ,Alanine ,Kinase ,Chemistry ,Triazines ,Drug Synergism ,Xenograft Model Antitumor Assays ,Oncology ,Rabeprazole ,Female ,Tyrosine kinase ,medicine.drug - Abstract
E-3810 is a novel small molecule that inhibits VEGF receptor-1, -2, and -3 and fibroblast growth factor receptor-1 tyrosine kinases at nmol/L concentrations currently in phase clinical II. In preclinical studies, it had a broad spectrum of antitumor activity when used as monotherapy in a variety of human xenografts. We here investigated the activity of E-3810 combined with different cytotoxic agents in a MDA-MB-231 triple-negative breast cancer xenograft model. The molecule could be safely administered with 5-fluorouracil, cisplatin, and paclitaxel. The E-3810–paclitaxel combination showed a striking activity with complete, lasting tumor regressions; the antitumor activity of the combination was also confirmed in another triple-negative breast xenograft, MX-1. The activity was superior to that of the combinations paclitaxel+brivanib and paclitaxel+sunitinib. Pharmacokinetics studies suggest that the extra antitumor activity of the combination is not due to higher paclitaxel tumor levels, which in fact were lower in mice pretreated with all three kinase inhibitors, and the paclitaxel plasma levels excluded reduced drug availability. Pharmacodynamic studies showed that E-3810, brivanib, and sunitinib given as single agents or in combination with paclitaxel reduced the number of vessels, but did not modify vessel maturation. Reduced tumor collagen IV and increased plasma collagen IV, associated with increased matrix metalloproteinases (MMP), particularly host MMP-9, indicate a proteolytic remodeling of the extracellular matrix caused by E-3810 that in conjunction with the cytotoxic effect of paclitaxel on the tumor cells (caspase-3/7 activity) may contribute to the striking activity of their combination. These data support the therapeutic potential of combining E-3810 with conventional chemotherapy. Mol Cancer Ther; 12(2); 131–40. ©2012 AACR.
- Published
- 2012
19. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells
- Author
-
Mauro Giacca, Graziella Pratesi, Mara Binda, Michelandrea De Cesare, Marco Folini, Sara Vignati, Lorenzo Citti, Alessandra Valentini, Nadia Zaffaroni, Marzia Pennati, Gennaro Colella, Monica Zoppè, Maria Grazia Daidone, Pennati, M., Binda, M., Colella, G., Zoppe, M., Folini, M., Vignati, S., Valentini, A., Citti, L., DE CESARE, M., Pratesi, G., Giacca, Mauro, Daidone, M. G., and Zaffaroni, N.
- Subjects
Male ,Cancer Research ,Survivin ,Genetic Vectors ,Mice, Nude ,Apoptosis ,Biology ,medicine.disease_cause ,Inhibitor of apoptosis ,Inhibitor of Apoptosis Proteins ,Prostate cancer ,Mice ,DU145 ,Transduction, Genetic ,Cell Line, Tumor ,Genetics ,medicine ,Animals ,Humans ,RNA, Catalytic ,Molecular Biology ,Base Pairing ,Base Sequence ,Cell Cycle ,Ribozyme ,Prostatic Neoplasms ,Genetic Therapy ,medicine.disease ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,Cell Transformation, Neoplastic ,Retroviridae ,Cancer cell ,biology.protein ,Cancer research ,Cisplatin ,Carcinogenesis ,Microtubule-Associated Proteins - Abstract
Survivin is a member of the inhibitor of apoptosis protein (IAP) family, which has been implicated in inhibition of apoptosis and control of mitotic progression. The finding that survivin is overexpressed in most human tumors but absent in normal adult tissues has led to the proposal of survivin as a promising therapeutic target for anticancer therapies. We decided to evaluate the effects of a ribozyme-based strategy for survivin inhibition in androgen-independent human prostate cancer cells. We constructed a Moloney-based retroviral vector expressing a ribozyme targeting the 3' end of the CUA(110) triplet in survivin mRNA, encoded as a chimeric RNA within adenoviral VA1 RNA. Polyclonal cell populations obtained by infection with the retroviral vector of two androgen-independent human prostate cancer cell lines (DU145 and PC-3) were selected for the study. Ribozyme-expressing prostate cancer cells were characterized by a significant reduction of survivin expression compared to parental cells transduced with a control ribozyme; the cells became polyploid, underwent caspase-9-dependent apoptosis and showed an altered pattern of gene expression, as detected by oligonucleotide array analysis. Survivin inhibition also increased the susceptibility of prostate cancer cells to cisplatin-induced apoptosis and prevented tumor formation when cells were xenografted in athymic nude mice. These findings suggest that manipulation of the antiapoptotic survivin pathway may provide a novel approach for the treatment of androgen-independent prostate cancer.
- Published
- 2004
20. Is PDGFR an important target for E-3810?
- Author
-
Maurizio D'Incalci, Giovanna Damia, Gabriella Camboni, and Gennaro Colella
- Subjects
medicine.drug_class ,Angiogenesis ,Mice, Nude ,Angiogenesis Inhibitors ,Antineoplastic Agents ,Naphthalenes ,Pharmacology ,Tyrosine-kinase inhibitor ,Rats, Sprague-Dawley ,Receptor, Platelet-Derived Growth Factor beta ,Mice ,Cell Line, Tumor ,Human Umbilical Vein Endothelial Cells ,medicine ,Animals ,Humans ,Receptor, Fibroblast Growth Factor, Type 1 ,Phosphorylation ,Kinase activity ,Letters to the Editor ,Protein Kinase Inhibitors ,biology ,Kinase ,Endothelial Cells ,Cell Biology ,Vascular Endothelial Growth Factor Receptor-2 ,In vitro ,Rats ,Disease Models, Animal ,Rabeprazole ,Quinolines ,biology.protein ,Cancer research ,Molecular Medicine ,Tyrosine kinase ,Platelet-derived growth factor receptor - Abstract
Dear Sir, In the issue Journal of Cellular and Molecular Medicine, Zhou et al. [1] reported the preclinical characterization of AL3810, an orally bioavailable small molecule inhibitor of tyrosine kinases involved in angiogenesis. The paper confirms most of the data that we have recently reported on the same compound [2] – that we named E-3810 – as correctly quoted by the authors. We were pleased to see that, in spite of the different experimental models used and of the different methodologies applied, Zhou et al. reported a consistent set of data confirming that E-3810 has a potent anti-angiogenic and antitumor activity through the inhibition of VEGFR and FGFR tyrosine kinases. However, in contrast to what observed and reported by us, we noticed that Zhou et al. observed that the drug is also an inhibitor of PDGFRα and β. As shown in the attached Table Table1,1, the drug concentrations that inhibited the kinase activity reported by Zhou et al. [1] and by us [2] were in the same nM range for VEGFR and FGFR kinases; on the contrary for the PDGFRα and β kinases these concentrations were much lower in Zhou et al. paper than in our report. The discrepancy could be related to the different biochemical assays used in the two studies; in fact, Zhou et al. used a colorimetric assay (enzyme-linked immunosorbent assay-ELISA) and all the tests were performed at fixed ATP concentration (5 μM), whereas we used more sensitive radiometric assays, with ATP concentrations always very close to single kinases Km. On the other hand, it should be noted that when the inhibition of the kinase activity was assessed in cells, the data obtained in the two studies were quite similar for the VEGF-dependent VEGFR phosphorylation and also for PDGFR phosphorylation: Zhou et al. found the latter inhibited at concentrations one log higher (i.e. 100 nM), i.e., very close to those found by us in both in in vitro biochemical and cellular assays. Table 1 In vitro drug IC50s on different kinases reported by the two papers A further interesting piece of information provided by Zhou et al. was that the drug reduced the number of perycites, assessed as PDGFRβ positive cells in tumour xenografts. This is in principle certainly correct [3]; however, since no double immunostaining of CD31 and PDGFRβ positivity were presented, it may be argued that the reduction in perycites is an indirect effect related to the endothelial cell loss induced by the inhibition of the VEGF-VEGFR pathway, for which clear biochemical data have been presented. Probably, xenograft tumours taken at different time points from the start of the treatment with E-3810 and the double CD31 and PDGFRβ immuno-staining would help to better define if the PDGF-PDGFR pathway can be directly inferred by E-3810. However, as consistently indicated, this new tyrosine kinase inhibitor has a good pharmacological profile and an outstanding antitumor activity in different experimental systems. The ongoing early clinical investigations confirm the good toxicity profile of E-3810 and support the view that the drug acts by inhibiting VEGFR and FGFR inducing a marked antitumor activity in cancer patients with tumour FGFR amplification even if heavily pretreated with standard chemotherapy and anti-angiogenic therapies [4].
- Published
- 2012
21. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression
- Author
-
Raffaella Villa, Lorenzo Citti, Gennaro Colella, Marco Folini, Mara Binda, Nadia Zaffaroni, Maria Grazia Daidone, and Marzia Pennati
- Subjects
Hammerhead ribozyme ,Skin Neoplasms ,Cell division ,Survivin ,Cell ,Apoptosis ,Dermatology ,In Vitro Techniques ,Biochemistry ,Inhibitor of Apoptosis Proteins ,medicine ,Tumor Cells, Cultured ,Humans ,RNA, Catalytic ,neoplasms ,Molecular Biology ,Melanoma ,biology ,Ribozyme ,Transfection ,Cell Biology ,biology.organism_classification ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Cell culture ,Gamma Rays ,biology.protein ,Cancer research ,ionizing radiation ,Microtubule-Associated Proteins ,ribozyme/survivin - Abstract
Survivin is a structurally unique member of the inhibitors of apoptosis protein family and is involved in the control of cell division and inhibition of apoptosis. The notion that survivin is overexpressed in most human tumors but absent in normal adult tissues with only a few exceptions has led to the proposal of survivin as a promising therapeutic target for novel anticancer therapies. In this context, we generated a hammerhead ribozyme targeting the 3' end of the CUA110 triplet in the survivin mRNA. Two human melanoma cell lines (JR8 and M14) overexpressing survivin were stably transfected with the pRc/CMV vector carrying the ribozyme sequence. Two polyclonal cell populations proven to endogenously express ribozyme and characterized by a markedly lower survivin protein level (-60% and -50%, respectively) than JR8 and M14 parental cells were selected for the study. Ribozyme-expressing cells showed a significantly (p0.01) increased sensitivity to gamma-irradiation (as detected by clonogenic cell survival) compared to JR8 and M14 cells. Moreover, in the JR8 cell line, the extent of radiation-induced apoptosis (in terms of percentage of apoptotic nuclei in cells stained with propidium iodide and level of caspase-3 catalytic activity) was markedly greater in ribozyme-expressing cells than in parental cells. These results demonstrate for the first time that attenuation of survivin expression renders human melanoma cells more susceptible to gamma-irradiation.
- Published
- 2003
22. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer
- Author
-
Marzia Pennati, Rosanna Supino, S. Pilotti, Gennaro Colella, Laura Gatti, Paola Perego, Maria Grazia Daidone, F. Zunino, and Nadia Zaffaroni
- Subjects
Low protein ,endocrine system diseases ,Organoplatinum Compounds ,Paclitaxel ,Chromosomal Proteins, Non-Histone ,Survivin ,Cell ,Apoptosis ,Docetaxel ,Biology ,Transfection ,Inhibitor of Apoptosis Proteins ,Cellular and Molecular Neuroscience ,Ovarian carcinoma ,medicine ,In Situ Nick-End Labeling ,Tumor Cells, Cultured ,Humans ,Phosphorylation ,Molecular Biology ,Pharmacology ,Cisplatin ,Ovarian Neoplasms ,Phosphotransferases ,Cell Biology ,medicine.disease ,Molecular biology ,Antineoplastic Agents, Phytogenic ,Neoplasm Proteins ,Oxaliplatin ,medicine.anatomical_structure ,Drug Resistance, Neoplasm ,Mutation ,Cancer research ,Molecular Medicine ,Immunohistochemistry ,Female ,Taxoids ,Ovarian cancer ,Microtubule-Associated Proteins ,medicine.drug - Abstract
Stable transfection of human ovarian carcinoma cells with survivin cDNA caused a four- to sixfold increase in cell resistance to taxotere and taxol (two-sided Student's t test, p0.05), with a concomitant reduction in the apoptotic response to taxol, but did not affect cell sensitivity to cisplatin or oxaliplatin. Such findings were indirectly supported by similar observations obtained with clinical tumours. In fact, high levels of survivin protein expression (30% positive cells), detected by immunohistochemistry in 90/124 (73%) advanced ovarian carcinomas, were significantly associated with clinical resistance to a taxol/platinum-based regimen but unrelated to tumour shrinkage following cisplatin-including combinations (non-taxol based). In the 95 patients receiving a taxol/platinum-based regimen, survivin overexpression correlated with a lower clinical or pathologic complete remission rate than absent/low protein expression (43 vs 75%, p = 0.0058 by logistic regression adjusted for tumour stage, histological grade and p53 expression). Conversely, in the 29 cases treated with cisplatin-containing regimens (not taxol based), survivin expression was unrelated to tumour response. Cellular studies and clinical data suggest a direct link between survivin expression and tumour cell susceptibility to taxol.
- Published
- 2002
23. Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions
- Author
-
A. Bearzatto, Nadia Zaffaroni, Marzia Pennati, Gennaro Colella, Roberto Leone, Mg Daidone, Donato Colangelo, and Carla Manzotti
- Subjects
Cancer Research ,DNA Repair ,Organoplatinum Compounds ,DNA repair ,Base Pair Mismatch ,Cell Survival ,Short communication ,cisplatin ,Antineoplastic Agents ,Biology ,Polymerase Chain Reaction ,chemistry.chemical_compound ,BBR 3464 ,medicine ,Tumor Cells, Cultured ,Humans ,Cytotoxicity ,Adaptor Proteins, Signal Transducing ,Mismatch Repair Endonuclease PMS2 ,Cisplatin ,Adenosine Triphosphatases ,Ovarian Neoplasms ,Nuclear Proteins ,Proteins ,medicine.disease ,Endonucleases ,Neoplasm Proteins ,DNA-Binding Proteins ,DNA Repair Enzymes ,ovarian cancer ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Immunology ,Cancer research ,DNA mismatch repair ,Female ,ERCC1 ,Ovarian cancer ,Carrier Proteins ,MutL Protein Homolog 1 ,DNA ,medicine.drug ,Nucleotide excision repair - Abstract
A collateral sensitivity or a very modest cross-resistance to BBR 3464 was found in 2 ovarian cancer cell lines with experimentally induced resistance to cisplatin. Loss of mismatch repair proteins (hMLH1, hPMS2) or overexpression of nucleotide excision repair proteins (ERCC1) was not detrimental for the cellular sensitivity to BBR 3464. Moreover, interesting differences in the kinetics of formation and removal of DNA lesions at the single-gene (N- ras) level were observed between BBR 3464 and CDDP. © 2001 Cancer Research Campaign www.bjcancer.com
- Published
- 2001
24. IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents
- Author
-
Maurizio D'Incalci, Gennaro Colella, Massimo Broggini, G. Giardina, P. Allavena, and Soumitra Sen
- Subjects
Immunology ,Killer activity ,Distamycins ,chemical and pharmacologic phenomena ,Antineoplastic Agents ,Cell Biology ,Interferon-beta ,Pharmacology ,Biology ,Cytotoxicity Tests, Immunologic ,Peripheral blood ,Recombinant Proteins ,law.invention ,Killer Cells, Natural ,law ,Doxorubicin ,Virology ,Nitrogen Mustard Compounds ,Recombinant DNA ,Camptothecin ,Cisplatin ,Melphalan ,Immunosuppressive Agents ,Etoposide - Abstract
We investigated whether recombinant human (rHu-IFN-beta) (IFN-beta) could counteract the inhibition of natural killer (NK) activity caused by antitumor agents. Peripheral blood lymphocytes (PBL) were incubated with different antitumor agents alone or in combination with IFN-beta for 3 days and then tested in a cytotoxicity assay against the K562 cell line. The following drugs were used, all of which caused a dose-dependent inhibition of NK activity: etoposide, camptothecin, doxorubicin, cis-DDP, tallimustine, and L-PAM. Concomitant treatment with (1000 U/ml) IFN-beta counteracted the inhibitory effect of etoposide and camptothecin but had no consistent effect on the inhibition mediated by the other drugs. Mean values of inhibition of NK activity at 1 microM camptothecin was 48%+/-3.4% and with IFN-beta was 10%+/-4.9%. With 100 microM etoposide, mean value of inhibition was 78%+/-3.3%, and with IFN-beta, it was 18%+/-1.5%. Cell viability, assessed by vital dye exclusion, and drug uptake, assessed with radiolabeled etoposide, were similar in cells treated with or without IFN-beta. The protective effect of IFN-beta on NK function was rather selective, as IFN-beta did not counteract the drug-mediated inhibition of PBL proliferation when stimulated by phytohemagglutinin (PHA). Other cytokines, IFN-alpha, IFN-gamma, and interleukin-2 (IL-2), had similar protective effect, although IFN-beta, was slightly more potent. On the other hand, IL-6, a cytokine sharing some properties with IFNs was ineffective. Camptothecin inhibited the expression of mRNA for granzyme B, a lytic protein involved in lymphoid-mediated cytotoxicity. Combined treatment with IFN-beta restored-at least in part-the transcription of granzyme B mRNA. These results show that the immunosuppressive effect of some antitumor agents could be partly counteracted by treatment with IFN-beta.
- Published
- 1998
25. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis
- Author
-
Marzia Pennati, Gennaro Colella, Marco Folini, Lorenzo Citti, Maria Grazia Daidone, and Nadia Zaffaroni
- Subjects
General Medicine - Published
- 2002
26. Abstract C192: Molecular mechanisms of antitumor activity of the combination of E-3810 and paclitaxel in MDA-MB-231 triple-negative breast xenograft
- Author
-
Gennaro Colella, Giovanna Damia, Ezia Bello, Pietro Spinelli, Alexander Berndt, Ennio Cavalletti, Gabriella Camboni, and Petra Richter
- Subjects
Antitumor activity ,Cancer Research ,Chemistry ,Cancer ,medicine.disease ,Small molecule ,chemistry.chemical_compound ,Oncology ,Paclitaxel ,Immunology ,medicine ,Cancer research ,Triple negative ,IC50 ,Tyrosine kinase ,Mda mb 231 - Abstract
E-3810 is a small molecule inhibitor of VEGFR-1, -2 and -3 and FGFR-1 tyrosine kinases with IC50 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C192.
- Published
- 2011
27. Abstract 595: E-3810 antitumor activity in human xenografts expressing different levels of FGF receptor 1
- Author
-
Giovanna Damia, Silvano Spinelli, Gennaro Colella, Ingmar Peitz, Roberta Cereda, Gerhard Kelter, Ennio Cavalletti, Maurizio D'Incalci, and Gabriella Camboni
- Subjects
Antitumor activity ,Cancer Research ,Oncology ,Chemistry ,Cancer research ,FGF Receptor - Abstract
E-3810 is a novel small molecule that selectively inhibits VEGF receptor-1, -2 and -3 and FGF receptor-1 (FGFR-1) tyrosine kinases currently undergoing a Phase 1 clinical trial in Europe. We have previously shown that the compound has strong anti-angiogenic effects in vivo and displays potent activity in all the human xenograft models in which it has been tested. We have also recently demonstrated that interference with FGF/FGFR pathway could result in a higher drug cytotoxic activity in those cell lines whose growth in vitro was dependent on the pathway. In order to corroborate these findings in an in vivo setting, a panel of human xenografts characterized by different expression of FGFR-1and FGF2 ligand is being screened for the response to E-3810 given at its optimal dose (20 mg/kg per os daily). Athymic female mice were transplanted s.c. with the different human xenografts and, when tumor masses reached the size of 80-120 mg, were randomized to receive vehicle or E-3810 for 14 days. Results are available for 7 models (see table reported below). All the selected tumors displayed similar growth rates, except for RXF_486 that grew more slowly. Tumor growth resumed upon drug withdrawal, at a rate seemingly higher where FGFR-1 was highly expressed. These preliminary results confirm the strong activity of E-3810 in a large panel of tumours, with growth control and, sometimes, regressions. Studies are ongoing to enlarge the panel of models and to confirm the observed trend suggesting a somewhat higher sensitivity to E-3810 in tumors expressing higher FGFR-1 and\or FGF ligand. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 595. doi:10.1158/1538-7445.AM2011-595
- Published
- 2011
28. Abstract 2574: Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231
- Author
-
Maurizio D'Incalci, Ennio Cavalletti, Ezia Bello, Giovanna Damia, Alexander Berndt, Gennaro Colella, and Gabriella Camboni
- Subjects
Cancer Research ,business.industry ,Cancer ,Pharmacology ,medicine.disease ,chemistry.chemical_compound ,Oncology ,Paclitaxel ,chemistry ,Cancer research ,Medicine ,business ,Tyrosine kinase ,Triple-negative breast cancer ,Mda mb 231 - Abstract
E-3810 is a novel small molecule that selectively inhibits VEGFR-1, -2 and -3 and FGFR-1 tyrosine kinases with IC50 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2574. doi:10.1158/1538-7445.AM2011-2574
- Published
- 2011
29. 191 E-3810, an inhibitor of the VEGF and FGF family receptors, inhibits the FGF-dependent growth of tumor cells
- Author
-
S. Spinelli, Maurizio D'Incalci, Roberta Cereda, G. Damia, G. Camboni, Gennaro Colella, and E. Cavalletti
- Subjects
Cancer Research ,Oncology ,biology ,Chemistry ,VEGF receptors ,biology.protein ,Cancer research ,Tumor cells ,Receptor ,Fibroblast growth factor - Published
- 2010
30. Abstract A257: Antitumor activity of E-3810, a new, potent and selective dual inhibitor of VEGF and FGF receptors
- Author
-
Ezia Bello, Ennio Cavalletti, Gennaro Colella, Maurizio D'Incalci, Valentina Scarlato, Gabriella Camboni, Silvano Spinelli, Roberta Cereda, Raffaella Giavazzi, and Giovanna Damia
- Subjects
Volume of distribution ,Cancer Research ,biology ,Chemistry ,Sunitinib ,Pharmacology ,Bioavailability ,Oncology ,Pharmacokinetics ,medicine ,biology.protein ,Receptor ,IC50 ,Tyrosine kinase ,Platelet-derived growth factor receptor ,medicine.drug - Abstract
E-3810, 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolyl]oxy]-N-methyl-naphthalene-1-carboxamide, is a novel small molecule that potently and selectively inhibits VEGFR1-3 and FGFR-1 tyrosine kinases (TKs) with IC50 in the 10-20 nM range. Concentrations at least 1-order higher were required to inhibit FGFR-2 and 3, PDGFRα and β and c-Kit receptors and no relevant activity was seen against different cancer-related TKs. E-3810 1-10 nM inhibited the ligand-dependent phosphorylation of VEGFR-2 and FGFR-1 and the downstream phosphorylation of Erk in HUVEC cells; inhibition of PDGFR- auto-phosphorylation in NIH-3T3 cells was detected at concentrations higher than 100 nM. E-3810 inhibited the VEGF- and FGF-driven growth of HUVEC cells (IC50 40-50 nM), while anti-proliferative activity on different human cancer cell lines was shown at 10-30 M concentrations. E-3810 was tested in different human tumor xenografts in nude mice, including colon HT-29, ovarian A-2780, renal A498, RXF393 and SKN12I carcinomas. A dose dependent antitumor effect was observed in a range from 10 to 40 mg/kg given orally for 30 consecutive days. The optimal dose schedule, 20 mg/kg for 30 days, was well tolerated and caused up to 90% suppression of tumor growth. Sustained growth inhibition was also seen when treatment was repeated after a 2-week dosing interval or when dosing was initiated at a larger tumor volume (average 400 mm3). Tumor regression was observed in the RXF393 xenograft. E-3810 showed antitumor activity equal or better than Sunitinib and Brivanib at their respective optimal doses. Pharmacokinetic studies in mice demonstrated high oral bioavailability, high volume of distribution and terminal half life of 4 hrs. After single and repeated administration E-3810 systemic exposure was proportional to the dose, without any accumulation after repeated doses. The good bioavailability and the remarkable antitumor activity of E-3810 in several tumor xenografts make this compound an interesting candidate for clinical development. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A257.
- Published
- 2009
31. 633 POSTER Effect of estrogen on cathepsin B activity and antitumor efficacy of Paclitaxel Poliglumex in human tumor xenografts
- Author
-
Dante Torriani, Marco Natangelo, Ulla Bastrup, Jack W. Singer, P. De Feudis, Laura Piazzoni, S. Di Giovine, Mara Cassin, Gabriella Pezzoni, and Gennaro Colella
- Subjects
Human tumor ,Cancer Research ,Oncology ,Paclitaxel Poliglumex ,Estrogen ,medicine.drug_class ,Chemistry ,Cathepsin B activity ,medicine ,Cancer research - Published
- 2006
32. 18 O - Characterization of a protein which recognizes DNA damaged by minor groove binders
- Author
-
Massimo Broggini, P. De Feudis, M. Bonfanti, S. Marchini, Patrizia Beccaglia, Maurizio D'Incalci, and Gennaro Colella
- Subjects
Cancer Research ,Carzelesin ,DNA damage ,Tallimustine ,Biology ,DNA-binding protein ,Molecular biology ,chemistry.chemical_compound ,Quinacrine Mustard ,Oncology ,Biochemistry ,chemistry ,Adozelesin ,Electrophoretic mobility shift assay ,DNA - Abstract
Some DNA minor groove binders have shown antiviral and antitumor activity. The distamycin derivative Tallimustine and the CC-1065 derivative Adozelesin and Carzelesin are under clinical investigationin phase II clinical trials. The mechanisms of repair of the DNA lesions caused by these drugs are unknown. By using the gel retardation assay, we have identified a protein able to recognize a fragment of DNA only if it was previously reacted with minor groove binders (MGB). This protein binds with very high affinity AT containing DNA treated with MGB such as Distamycin A or Hoechst 33258 but not with a major groove binders (such as e.g. quinacrine mustard). This protein was found to be present in extracts of human, murine or hamster cells, although the human protein appears to have a molecular weight slightly lower than that of the other species. This protein is expressed both in cancer and normal tissues. By using ultrafiltration techniques as well as Southwestern analysis it was estimated that the apparent molecular weight is close to 100 Kda. Work is in progress to purify this protein which might be involved in the recognition and repair of DNA damage caused by minor groove binders.
- Published
- 1996
33. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
- Author
-
Fabio Bozzi, Raffaella Gatta, Sarah Uboldi, S. Vicario, E. Ronchetti, Sergio Marchini, Carlos M. Galmarini, Gianpaolo Dagrada, Maurizio D'Incalci, Ilaria Craparotta, Nicolò Panini, Luca Beltrame, S. Pilotti, and Gennaro Colella
- Subjects
0301 basic medicine ,Cancer Research ,Oncogene Proteins, Fusion ,Desmoplastic small-round-cell tumor ,Cell ,Apoptosis ,Dioxoles ,Desmoplastic Small Round Cell Tumor ,Biology ,Bioinformatics ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Cell Line, Tumor ,Tetrahydroisoquinolines ,medicine ,Genetics ,Humans ,WT1 Proteins ,Antineoplastic Agents, Alkylating ,Transcription factor ,Trabectedin ,Cell Proliferation ,JN-DSRCT-1 ,medicine.disease ,Fusion protein ,Gene Expression Regulation, Neoplastic ,Gene expression profiling ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,DSRCT ,RNA-Binding Protein EWS ,Carcinogenesis ,Research Article ,medicine.drug - Abstract
Background Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be described as a member of the family of small round blue cell tumors. The molecular diagnostic marker is the t(11;22)(p13;q12) translocation, which creates an aberrant transcription factor, EWS-WT1, that underlies the oncogenesis of DSRCT. Current treatments are not very effective so new active drugs are needed. Trabectedin, now used as a single agent for the treatment of soft tissue sarcoma, was reported to be active in some pre-treated DSRCT patients. Using JN-DSRCT-1, a cell line derived from DSRCT expressing the EWS-WT1 fusion protein, we investigated the ability of trabectedin to modify the function of the chimeric protein, as in other sarcomas expressing fusion proteins. After detailed characterization of the EWS-WT1 transcripts structure, we investigated the mode of action of trabectedin, looking at the expression and function of the oncogenic chimera. Methods We characterized JN-DSRCT-1 cells using cellular approaches (FISH, Clonogenicity assay) and molecular approaches (Sanger sequencing, ChIP, GEP). Results JN-DSRCT-1 cells were sensitive to trabectedin at nanomolar concentrations. The cell line expresses different variants of EWS-WT1, some already identified in patients. EWS-WT1 mRNA expression was affected by trabectedin and chimeric protein binding on its target gene promoters was reduced. Expression profiling indicated that trabectedin affects the expression of genes involved in cell proliferation and apoptosis. Conclusions The JN-DSRCT-1 cell line, in vitro, is sensitive to trabectedin: after drug exposure, EWS-WT1 chimera expression decreases as well as binding on its target promoters. Probably the heterogeneity of chimera transcripts is an obstacle to precisely defining the molecular mode of action of drugs, calling for further cellular models of DSRCT, possibly growing in vivo too, to mimic the biological complexity of this disease. Electronic supplementary material The online version of this article (doi:10.1186/s12885-017-3091-1) contains supplementary material, which is available to authorized users.
- Full Text
- View/download PDF
34. Effect of G:C→A:T transition, potentially arising from O6-guanine alkylation, in the transcription regulation of c-fos serum response element
- Author
-
Bonfanti M, Gennaro Colella, Broggini M, and D'Incalci M
- Subjects
DNA Replication ,Binding Sites ,Guanine ,Base Sequence ,Transcription, Genetic ,Recombinant Fusion Proteins ,Genes, fos ,3T3 Cells ,Oligonucleotides, Antisense ,Regulatory Sequences, Nucleic Acid ,Transfection ,Polymerase Chain Reaction ,Mice ,Oligodeoxyribonucleotides ,Genes, Reporter ,Mutagenesis, Site-Directed ,Animals ,Point Mutation ,DNA Primers - Abstract
O6-meGs, if not repaired before cell undergo DNA synthesis, can cause erroneous pairing of thymine resulting in a G:C--A:T transition, after the next DNA replication. It is known that the presence of O6-meG in promoter sequences inhibits the specific binding of transcription factors. Little is known on the effect of G:C--A:T transitions on this binding. c-fos SRE was used as a model to study the effect of different G:C--A:T transitions (at the positions -305, -306, -316, -319 and -320) in terms of SRE specific DNA-binding and functional ability to activate transcription of a reporter gene. The electromobility shift assay and a transient transfection assay were used. The G:C--A:T transition at -320 caused 92% inhibition, while mutations at the positions -305, -306, -316 and -319 caused respectively 55, 43, 19 and 44% inhibition. The findings indicate that some G:C--A:T transitions, potentially arising from O6-guanine methylation, can impair the regulation of c-fos transcription.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.